Grace Therapeutics, Inc.(GRCE)Earnings, Financials & Key Ratios

GRCE•NASDAQ

$2.34

Price updated Jun 27, 2026

SectorHealthcare IndustryBiotechnology Sub-IndustryCommercial Rare Disease Biopharma

AboutGrace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal betamethasone spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. The company was incorporated in 2002 and is headquartered in Princeton, New Jersey.Show more

Revenue$0
EBITDA-$11M+53.4%
Net Income-$8M+42.8%
EPS (Diluted)-0.47+58.4%
ROE-11.94%+43.8%

GRCE Price & Volume

Grace Therapeutics, Inc. (GRCE) stock price & volume — 10-year historical chart

Loading chart...

Persistent Clinical Burn Challenges Long-term Solvency Outlook

Investment Thesis • Updated 2026Q4

VerdictNegative

Growth:Contracting

Profitability:Negative

Financial Position:Vulnerable

Cash Flow:Burning

Primary Risk:Binary clinical trial outcome

"Grace Therapeutics remains a pre-revenue biotechnology entity characterized by significant clinical development risks and a reliance on external capital to fund operations. While the company has moderated R&D spending from a peak of $3.7 million in 2025Q1 to $420,000 in 2026Q4, the lack of commercial revenue and an accumulated deficit of $228.5 million suggest a precarious financial trajectory. Investors should monitor the company's ability to secure strategic partnerships, as the current $17.0 million cash position may be insufficient to support late-stage clinical milestones without further dilutive financing."

Verdict Logic

the company's fundamental viability is threatened by a persistent cash burn and an accumulated deficit of $228.5 million, which significantly outweighs the current $17.0 million cash reserve.

GRCE Growth Metrics

Grace Therapeutics, Inc. (GRCE) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-

5 Years-

3 Years-

TTM-

Profit CAGR

10 Years-

5 Years-

3 Years-

TTM25.3%

EPS CAGR

10 Years-

5 Years-

3 Years-

TTM46.37%

Return on Capital

10 Years-76.78%

5 Years-32.63%

3 Years-24.56%

Last Year-16.46%

Peers Comparison

Key metrics vs top competitors for Grace Therapeutics, Inc. (GRCE)

Full Screener →

Company	Price	Market Cap	P/E Ratio	Rev Growth (1Y)	Net Margin	ROE	Div Yield
GRCEGrace Therapeutics, Inc.Current	$2.34	$38.08M	-4.98	—	—	-11.94%	—
RAREUltragenyx Pharmaceutical Inc.	$30.77	$3.03B	-5.28	20.13%	-91.03%	—	—
FOLDAmicus Therapeutics, Inc.	$14.49	$4.55B	-164.85	20.05%	-4.27%	-12.02%	—
ACADACADIA Pharmaceuticals Inc.	$25.32	$4.34B	11.06	11.87%	34.3%	35.65%	—
PTCTPTC Therapeutics, Inc.	$84.43	$7B	10.85	114.51%	-22.58%	—	—
ARVNArvinas, Inc.	$8.00	$516.17M	-6.25	-0.3%	-247.54%	-44.39%	—